ArticleMolecular biology of the cell2008
Regulation of Chk1 by its C-terminal domain.
Article in Molecular biology of the cell, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 29 citations in OpenAlex.
- A C-degron regulates Chk1 kinase by allowing stability of inactive Chk1 and by making it short- lived upon activation.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- CHK1 as a Metabolic and Immunological Regulator: Implications for Cancer Therapy.Oncology research · 2026Review
- AoChk1 Is Required for Sporulation, Trap Formation, and Metabolic Process inJournal of fungi (Basel, Switzerland) · 2025Article
- Case report: A germlineFrontiers in oncology · 2024Article
- Genomic structure, expression, and functional characterization of checkpoint kinase 1 from Penaeus monodon.PloS one · 2018Article
- The kinase domain residue serine 173 ofBiology open · 2017Article
- Intramolecular autoinhibition of checkpoint kinase 1 is mediated by conserved basic motifs of the C-terminal kinase-associated 1 domain.The Journal of biological chemistry · 2017Article
- The drinking water contaminant dibromoacetonitrile delays G1-S transition and suppresses Chk1 activation at broken replication forks.Scientific reports · 2017Article
- Function and regulation mechanism of Chk1 during meiotic maturation in porcine oocytes.Cell cycle (Georgetown, Tex.) · 2017Article
- Conformational Change of Human Checkpoint Kinase 1 (Chk1) Induced by DNA Damage.The Journal of biological chemistry · 2016Article
- KA1-targeted regulatory domain mutations activate Chk1 in the absence of DNA damage.Scientific reports · 2015Article
- Roles of Chk1 in cell biology and cancer therapy.International journal of cancer · 2014Review
- Regulation of zygotic genome activation and DNA damage checkpoint acquisition at the mid-blastula transition.Cell cycle (Georgetown, Tex.) · 2014Article
- Checkpoint kinase 1 in DNA damage response and cell cycle regulation.Cellular and molecular life sciences : CMLS · 2013Review
- Regulatory motifs in Chk1.Cell cycle (Georgetown, Tex.) · 2013Article
- Initiation of DNA damage responses through XPG-related nucleases.The EMBO journal · 2013Article
- Autoregulatory mechanisms of phosphorylation of checkpoint kinase 1.Cancer research · 2012Article
- The DNA damage checkpoint regulates a transition between yeast and hyphal growth in Schizosaccharomyces japonicus.Molecular and cellular biology · 2010Article
- Transformation/transcription domain-associated protein (TRRAP)-mediated regulation of Wee1.Genetics · 2010Article
- Requirement of a mitogen-activated protein kinase for appressorium formation and penetration of insect cuticle by the entomopathogenic fungus Beauveria bassiana.Applied and environmental microbiology · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Chk1 is a protein kinase that is the effector molecule in the G2 DNA damage checkpoint. Chk1 homologues have an N-terminal kinase domain, and a C-terminal domain of approximately 200 amino acids that contains activating phosphorylation sites for the ATM/R kinases, though the mechanism of activation remains unknown. Structural studies of the human Chk1 kinase domain show an open conformation; the activity of the kinase domain alone is substantially higher in vitro than full-length Chk1, and coimmunoprecipitation studies suggest the C-terminal domain may contain an autoinhibitory activity. However, we show that truncation of the C-terminal domain inactivates Chk1 in vivo. We identify additional mutations within the C-terminal domain that activate ectopically expressed Chk1 without the need for activating phosphorylation. When expressed from the endogenous locus, activated alleles show a temperature-sensitive loss of function, suggesting these mutations confer a semiactive state to the protein. Intragenic suppressors of these activated alleles cluster to regions in the catalytic domain on the face of the protein that interacts with substrate, suggesting these are the regions that interact with the C-terminal domain. Thus, rather than being an autoinhibitory domain, the C-terminus of Chk1 also contains domains critical for adopting an active configuration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.